Next Article in Journal
Gold Nanoparticles-Enhanced Gene Transfer Driven by MHz-Frequency Nanosecond Pulsed Electric Fields
Previous Article in Journal
Influence of Stress-Induced Senescence on the Secretome of Primary Mesenchymal Stromal Cells
Previous Article in Special Issue
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 15
Issue 12
10.3390/biom15121735
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation

by
Aurelio Lo Buglio
*,†,
Francesco Bellanti
†,
Rosanna Villani
,
Cristiano Capurso
,
Grazia Pia Magnati
,
Sara Cioffi
,
Gabriele Tedesco
,
Carlo Alberto Torsello
,
Gianluigi Vendemiale
and
Gaetano Serviddio
Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2025, 15(12), 1735; https://doi.org/10.3390/biom15121735
Submission received: 25 November 2025 / Revised: 6 December 2025 / Accepted: 11 December 2025 / Published: 13 December 2025
(This article belongs to the Special Issue Liver Damage and Associated Metabolic Disorders)
Browse Figures
Versions Notes

Abstract

Background: Malnutrition is a prevalent and under-recognized condition in patients with type 2 diabetes mellitus (T2DM), contributing to various complications, including liver fibrosis. In this study, we aimed to evaluate the association between malnutrition and liver fibrosis in patients with T2DM, and to assess whether inflammation mediates this relationship. Methods: In this prospective single-centre study, 87 adult outpatients with T2DM underwent nutritional assessment using the Subjective Global Assessment (SGA) and liver stiffness measurement by transient elastography. Metabolic dysfunction-associated steatotic liver disease (MASLD) was diagnosed according to EASL guidelines. C-reactive protein (CRP) was measured as a marker of systemic inflammation. Multivariable linear regression and mediation analysis were performed, adjusting for age and sex. Results: Malnutrition was present in 50.6% of patients, MASLD in 66.7%, and both conditions coexisted in 36.8%. Malnutrition (B = 2.29, p < 0.001), MASLD (B = 1.54, p = 0.001), smoking (B = 1.06, p = 0.014), and CRP (B = 0.32, p < 0.001) were independently associated with increased liver stiffness. CRP partially mediated the effect of malnutrition on liver stiffness (indirect effect = 0.54; 95% CI 0.20–0.95), accounting for 18% of the total effect. Conclusions: In T2DM, malnutrition is a strong independent predictor of liver fibrosis, with its effect partially mediated by systemic inflammation. Addressing nutritional status and inflammatory burden may help slow fibrotic progression in this high-risk population.

1. Introduction

Malnutrition is common in type 2 diabetes mellitus (T2DM) and is associated with reduced quality of life, higher hospitalisation rates, disability, and increased all-cause and cardiovascular mortality [1,2,3,4]. In this population, poor nutritional status accelerates skeletal muscle loss, a key driver of sarcopenia [5]. Loss of muscle mass contributes to a chronic inflammatory state, which worsens metabolic dysfunction and insulin resistance, creating a self-perpetuating cycle [6,7].
In this scenario, chronic low-grade inflammation is a hallmark of T2DM and plays a major role in the progression of diabetic complications, particularly liver disease [8,9]. Inflammatory cytokines such as IL-6, TNF-α, and CRP are consistently elevated in T2DM and promote lipid accumulation, oxidative stress and fibrosis [10,11,12,13].
Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as NAFLD—is highly prevalent in T2DM, with fibrosis representing the main prognostic determinant of long-term liver-related outcomes [14,15]. Malnutrition and inflammation engage in a dynamic, bidirectional interaction that amplifies their respective effects: poor nutritional status exacerbates systemic inflammation, while persistent inflammation worsens malnutrition via cytokine-mediated mechanisms [16].
Emerging evidence suggests that malnutrition, like inflammation, may be directly implicated in the pathogenesis of liver fibrosis by impairing immune regulation and antioxidant defences [17].
Malnutrition could amplify both hepatic and systemic inflammatory responses, leading to hepatic stellate cell activation, extracellular matrix deposition, and fibrogenesis [18].
However, the relative contribution of malnutrition, inflammation, and their interaction to the development of liver fibrosis in T2DM remains poorly defined. To date, no studies have explored whether systemic inflammation mediates the relationship between malnutrition and liver stiffness in patients with T2DM. This study aimed to evaluate the association between malnutrition and liver fibrosis, and to determine whether systemic inflammation mediates this relationship.

2. Materials and Methods

2.1. Study Design

A prospective, single-centre study was conducted in the Liver Unit of University of Foggia, Foggia, Italy. We recorded clinical data from 87 adults consecutively attending outpatient clinics between January and June 2025 and affected by T2DM. Inclusion criteria were age ≥ 18 years and diagnosis of T2DM. Exclusion criteria included active malignancy, acute infection, pre-existing chronic liver diseases (including viral or autoimmune hepatitis), and cirrhosis. The study protocol was approved by the Institutional Review Board of Policlinico Riuniti (Foggia, Italy), and all procedures were conducted in accordance with the Declaration of Helsinki.
At enrolment, venous blood samples were obtained to measure haemoglobin, total white blood cell count (WBC), neutrophil count, lymphocyte count, platelet count, glucose, albumin, creatinine, HbA1c, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and C-reactive protein (CRP).
The triglyceride–glucose (TyG) index was calculated using ln f a s t i n g   t r i g l y c e r i d e s   [ m g / d L ]   ×   f a s t i n g   g l u c o s e   [ m g / d L ]   2 [19].
Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2).
Comorbidities assessed included hypertension, chronic kidney disease (CKD), heart failure, ischaemic chronic heart disease, atrial fibrillation, stroke, and chronic obstructive pulmonary disease (COPD), as well as self-reported smoking habits. Type 2 diabetes mellitus (T2DM) was diagnosed in the presence of at least one of the following criteria: fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) confirmed on two separate occasions; glycated hemoglobin (HbA1c) ≥ 6.5%; or a 2-h plasma glucose value ≥ 200 mg/dL (11.1 mmol/L) during a standard 75 g oral glucose tolerance test (OGTT). Ongoing treatment with antidiabetic agents was also considered as evidence of diabetes; however, since metformin can be prescribed for other conditions such as polycystic ovary syndrome, obesity, or prediabetes, patients on metformin alone were classified as diabetic only if at least one of the above biochemical criteria was satisfied. Metabolic dysfunction-associated steatotic liver disease (MASLD) was defined according to EASL 2024 guidelines [20]. The Charlson Comorbidity Index was used to quantify comorbidity burden.
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of “Policlinico Riuniti” in Foggia (N◦161/CE/2023, approval date 23 October 2023). Informed consent was obtained from all participants in their medical records.

2.2. Nutritional Assessment

Nutritional status was evaluated using the Subjective Global Assessment (SGA), which incorporates both subjective and objective components. The SGA was chosen because it is validated across the full adult age range, including both adults under 65 and older adults, and it is widely used in outpatient populations with chronic conditions such as T2DM [21,22]. The subjective evaluation covered changes in dietary intake, unintentional weight loss, gastrointestinal symptoms affecting oral intake (e.g., diarrhoea, vomiting, nausea, dysphagia, oral issues), and functional capacity. The objective evaluation involved physical examination for loss of subcutaneous fat, muscle wasting, and presence of oedema or ascites. Patients were classified as A (well nourished), B (moderate malnutrition), or C (severe malnutrition) [21]. For analysis, categories B and C were combined into a single ‘malnutrition’ category.

2.3. Liver Stiffness and Steatosis Assessment

Liver stiffness was measured by transient elastography (FibroScan® 630 Touch, Echosens, Paris, France) after ≥3 h of fasting. Only measurements with ≥10 valid acquisitions, a success rate > 60%, and an interquartile range/median ratio < 0.30 were considered reliable. Steatosis was assessed using the Controlled Attenuation Parameter (CAP). A cut-off of 248 dB/m was adopted, as this value corresponds to the optimal Youden-index threshold proposed by Karlas et al. for detecting ≥ S1 steatosis and has been widely validated across multiple cohorts. This cut-off was selected to ensure high sensitivity for identifying early steatotic changes, consistent with the aims of the present study [20,23].

2.4. Statistical Analysis

Continuous variables were tested for normality and expressed as mean ± standard deviation or median (interquartile range) as appropriate. Categorical variables were expressed as number (percentage). Group comparisons were performed using independent-samples t-test for normally distributed continuous variables, Mann–Whitney U test for non-normally distributed variables, and chi-square test for categorical variables.
A priori sample-size considerations were performed using G*Power vers 3.197 (linear multiple regression, fixed model, single regression coefficient). Assuming a medium effect size (f2 = 0.15), α = 0.05, two-tailed testing, power = 0.80, and four predictors of interest, the required sample size was estimated at 55 participants.
Multiple linear regression was used to examine associations between nutritional status, inflammatory markers, and metabolic parameters with liver stiffness. Variables with p < 0.05 in age- and sex-adjusted univariate models were entered into the multivariable model, which was further adjusted for age and sex.
Mediation analysis was performed using the non-parametric bootstrap method (5000 resamples) to test whether CRP mediated the association between malnutrition and liver stiffness (Figure 1). The proportion mediated was calculated as the ratio of the indirect effect to the total effect. Statistical significance was set at two-sided p ≤ 0.05. Analyses were performed using R (version 4.3) within the RStudio 2025.09.2+418 environment (Posit Software, Boston, MA, USA).

3. Results

3.1. Demographic and Clinical Characteristics of the Study Population

In this prospective observational study, a total of 87 patients were enrolled, of whom 28 (32.2%) were female. The median age was 67 years [IQR: 60–72]. According to SGA, 44 patients (50.6%) were classified as malnourished, while the remaining 49.4% were considered well-nourished. The overall prevalence of MASLD in the cohort was 66.7%. An analysis of the overlap between MASLD and malnutrition revealed that 36.8% of patients were affected by both conditions. Interestingly, 29.9% had MASLD in the absence of malnutrition, while 13.8% were malnourished without signs of MASLD. These findings are visually summarized in the Venn diagram (Figure 2).
The most frequent comorbidities were dyslipidaemia (80.5%) and hypertension (62.1%). Other conditions, including chronic kidney disease, ischemic heart disease, atrial fibrillation, COPD, and stroke, were less prevalent. Smoking was reported by 27.6% of patients. Data are summarized in Table 1.
Patients with malnutrition showed lower levels of WBC, neutrophils, lymphocytes, total cholesterol, and LDL cholesterol, as well as higher levels of HbA1c, CRP, and the TyG index. They also exhibited a greater comorbidity burden, as indicated by higher Charlson Comorbidity Index scores. Moreover, those with impaired nutritional status showed significantly higher liver stiffness values. Baseline characteristics are reported in Table 2.

3.2. Association of Nutritional and Inflammatory Factors with Liver Fibrosis

To explore potential predictors of liver fibrosis, we conducted a multiple linear regression analysis using liver stiffness as the dependent variable. Initially, several clinical and biochemical parameters were assessed through univariate analyses. Variables found to be statistically significant were subsequently included in the multivariable model (Table 3). All analyses were adjusted for age and sex to account for potential confounding.
In the final model, malnutrition emerged as the strongest independent predictor of increased liver stiffness (B = 2.29, p < 0.001). This was followed by the presence of MASLD (B = 1.54, p = 0.001) and smoking status (B = 1.06, p = 0.014). Additionally, CRP was significantly associated with liver stiffness (B = 0.32, p < 0.001). In contrast, neither the TyG index nor HbA1c showed significant independent associations (Figure 3). A comprehensive summary of the regression results is provided in Table 3.

3.3. Mediation Analysis

We investigated whether inflammation, assessed by CRP levels, acted as a mediator in the relationship between malnutrition and liver stiffness, adjusting for age and sex.
The total effect of malnutrition on liver stiffness was statistically significant (B = 2.97, SE = 0.47, t = 6.35, p < 0.001), F(3, 83) = 13.78, p < 0.001, R2 = 0.33, indicating that poor nutritional status was associated with greater liver stiffness. When CRP was added to the model as a mediator, the association between malnutrition and liver stiffness remained significant (B = 2.42, SE = 0.46, p < 0.001) but was attenuated, suggesting partial mediation. This mediation model was significant, F(4, 82) = 15.41, p < 0.001, R2 = 0.43. Malnutrition was positively associated with CRP levels (B = 1.64, SE = 0.53, p = 0.003), F(3, 83) = 3.67, p = 0.015, R2 = 0.12, and CRP, in turn, was positively associated with liver stiffness (B = 0.33, SE = 0.09, p < 0.001), after adjusting for malnutrition and covariates.
The indirect effect of malnutrition on liver stiffness via CRP was statistically significant (Effect = 0.54, BootSE = 0.20, 95% CI [0.20, 0.95]). The partially standardized indirect effect was 0.21 (95% CI [0.08, 0.37]). This indirect path accounted for approximately 18% of the total association between malnutrition and liver stiffness. Figure 4 illustrates the path diagram with unstandardized coefficients and p-values for each link.
Following the framework proposed by Fritz and MacKinnon [24], Figure 5 depicts liver stiffness (Y-axis) against CRP levels (X-axis), with separate regression lines for participants with low (dashed blue) and high (solid red) malnutrition scores. The horizontal distance between vertical reference lines corresponds to the “a” path (effect of malnutrition on CRP), while the slope of each regression line represents the “b” path (effect of CRP on liver stiffness, controlling for malnutrition). The vertical gap between regression lines at a given CRP value reflects the direct effect of malnutrition (c′), whereas the total effect (c) represents the association without accounting for CRP. The difference between c and c′ corresponds to the mediated (indirect) component of the association.
The figure displays liver stiffness (Y-axis) as a function of CRP levels (X-axis), with separate regression lines for individuals with high (red solid line) and low (blue dashed line) malnutrition. The slopes reflect the association between CRP and liver stiffness within each malnutrition group.

4. Discussion

In this prospective study of patients with T2DM, we found that malnutrition was strongly and independently associated with higher liver stiffness, even after accounting for age, sex, MASLD, and other comorbidities. Importantly, systemic inflammation, as reflected by CRP levels, partially mediated this relationship, suggesting a mechanistic link between poor nutritional status and progression of hepatic fibrosis in this high-risk population.
Our findings add to a growing body of evidence indicating that malnutrition is not only common in individuals with T2DM, but also clinically relevant for liver-related outcomes [4,25].
In our cohort, malnourished patients showed higher CRP levels and lower lymphocyte counts, consistent with the effect of malnutrition on inflammatory status. The significantly lower total and LDL cholesterol observed in malnourished patients is coherent with the poor nutritional status. These biochemical differences further highlight the close interplay between malnutrition and systemic inflammation in T2DM.
Current evidence indicates that malnourished patients with chronic liver disease have a more rapid progression of fibrosis, increased rates of complications, and reduced survival compared with well-nourished patients [26]. By evaluating an outpatient diabetic population without advanced liver disease, we found that the effects of malnutrition on liver stiffness are already detectable, with higher mean values compared with well-nourished counterparts. This suggests that malnutrition may exert a measurable hepatic impact before progression to advanced stages. The partial mediation by CRP observed in our analysis supports a mechanistic pathway whereby malnutrition may contribute to fibrosis progression through heightened systemic inflammation. These findings address an important evidence gap and support the concept that malnutrition should be considered a relevant risk factor for hepatic fibrosis even in community-dwelling patients with T2DM. Malnutrition may exacerbate systemic inflammation through impaired immune function, reduced antioxidant capacity, and increased susceptibility to infections [27,28,29].
Conversely, chronic low-grade inflammation can worsen nutritional status via cytokine-induced anorexia, increased resting energy expenditure, and muscle catabolism [30,31]. This reciprocal relationship creates a self-perpetuating cycle that may also involve the liver, where heightened systemic inflammation contributes to hepatic stellate cell activation, extracellular matrix deposition, and accelerated fibrosis progression [32].
From a pathophysiological perspective, the role of inflammation in fibrogenesis is well established. IL-6, TNF-α, and CRP have been implicated in the activation of hepatic stellate cells, modulation of Kupffer cell activity, and alteration of the hepatic microenvironment [33,34]. In addition, inflammation has been shown to promote hepatic steatosis through cytokine-mediated metabolic alterations and oxidative stress, and steatosis itself is a recognized risk factor for fibrosis progression [35,36]. In the setting of T2DM and MASLD, persistent metabolic stress and oxidative injury may synergize with these inflammatory pathways, amplifying fibrosis progression [37]. In our cohort, the persistence of an independent association between CRP and liver stiffness—even after adjusting for MASLD—suggests that inflammatory pathways exert fibrogenic effects beyond those attributable to metabolic steatosis alone. An additional finding of our multivariable analysis was that active smoking was independently associated with increased liver stiffness, regardless of malnutrition, MASLD, and systemic inflammation. This aligns with prior evidence linking smoking to oxidative stress, immune dysregulation, and hepatic microvascular alterations, all of which may drive hepatic stellate cell activation and extracellular matrix deposition [38,39,40]. Smoking contributes to adverse lipid and inflammatory alterations closely linked to insulin resistance, providing an additional plausible pathway through which smoking may exacerbate liver injury in T2DM [41]. In T2DM, smoking can also amplify chronic low-grade inflammation and worsen endothelial dysfunction, thereby accelerating fibrogenesis [42].
Clinically, these findings underscore the need for integrated management strategies in T2DM that address both nutritional status and inflammatory burden. A proactive approach should include early screening for malnutrition, personalised dietary counselling, and targeted nutritional interventions to preserve lean body mass, optimise protein quality and quantity, and correct micronutrient deficiencies. Nutritional interventions aimed at preserving lean body mass, improving protein intake, and correcting micronutrient deficiencies could potentially mitigate systemic inflammation and slow fibrosis progression [43,44,45]. Anti-inflammatory dietary patterns, such as the Mediterranean diet, have been shown to reduce CRP levels and improve metabolic parameters in T2DM [46]. Improving micronutrient status may also help mitigate systemic inflammation and improve redox balance in T2DM [47]. In addition, previous evidence showed that low levels of vitamin D are associated with increased pro-inflammatory cytokine expression and greater liver fibrosis in patients with chronic liver disease [48]. Future studies should specifically investigate if serum vitamin D levels in malnourished patients with diabetes correlate with liver stiffness progression. Our results also have implications for MASLD risk stratification. While fibrosis remains the strongest predictor of liver-related outcomes, recent data suggest that higher degrees of steatosis may be associated with increased mortality and cardiometabolic complications [49,50].
Thus, a combined evaluation of steatosis burden, fibrosis stage, and nutritional status may provide a more comprehensive risk profile for patients with T2DM.
This study has some limitations. First, the sample size and drawn from a single care centre, which may limit generalizability. Second, CRP is a nonspecific marker of inflammation; future studies incorporating a broader panel of inflammatory cytokines may provide a more detailed mechanistic understanding. Third, the duration of antidiabetic therapy was not considered, which could potentially influence the degree of liver fibrosis. Lastly, the cross-sectional nature of liver stiffness assessment precludes definitive conclusions about causality, although the biological plausibility of the proposed pathway is supported by experimental and clinical evidence. Moreover, we adopted 248 dB/m as CAP threshold for steatosis detection, privileging sensitivity for ≥S1. This cut-off was originally proposed by Karlas et al. [23] as the optimal Youden index value for detecting any degree of steatosis, and has since been validated in several cohorts as a reliable threshold to rule out S0. Given our study aim to capture the earliest hepatic changes associated with malnutrition in T2DM, maximizing sensitivity for even mild steatosis was prioritized. We acknowledge that higher cut-offs (≈275–280 dB/m) are often used to ‘rule in’ moderate-to-severe steatosis with higher PPV, and this methodological choice may affect comparability with other cohorts.

5. Conclusions

Malnutrition is a strong and independent predictor of liver stiffness in patients with T2DM, and this association is partially mediated by systemic inflammation. Early identification and correction of nutritional deficits, coupled with strategies to reduce chronic inflammation, may represent a novel and cost-effective approach to attenuate fibrosis progression and improve long-term outcomes in this vulnerable population. Our findings also support incorporating early malnutrition screening and simple inflammatory markers into the routine MASLD work-up for patients with T2DM, as these elements may enhance clinical risk stratification and guide more timely preventive interventions. Large, longitudinal studies are needed to confirm these findings and determine whether early nutritional and anti-inflammatory interventions can translate into improved liver-related and overall outcomes

Author Contributions

Conceptualization: A.L.B., F.B.; Methodology: A.L.B., F.B.; Formal analysis: A.L.B.; Investigation: G.P.M., S.C., G.T., C.A.T.; Writing—original draft preparation: A.L.B.; Writing—review and editing: A.L.B., F.B., R.V., C.P., G.V. and G.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by “HEAL ITALIA—Health Extended Alliance for Innovative Therapies, Advanced Lab-research and Integrated Approaches of Precision Medicine” Cod. PE_00000019 with financial contribution of European Union—NextGenerationUE as part of PNRR MUR—M4C2—Investimento 1.3—Public Call “Partenariati Estesi”—D.D. n. 341/2022. We also thank the financial support of the Dept. of Medical and Surgical Sciences of the University of Foggia.

Institutional Review Board Statement

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of “Policlinico Riuniti” in Foggia (N◦161/CE/2023, approval date 23 October 2023).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The dataset analysed during the current study is available from the corresponding author on reasonable request due privacy restrictions.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Zhang, T.; Qin, J.; Guo, J.; Dong, J.; Chen, J.; Ma, Y.; Han, L. Prevalence and Influencing Factors of Malnutrition in Diabetic Patients: A Systematic Review and Meta-analysis. J. Diabetes 2024, 16, e13610. [Google Scholar] [CrossRef]
  2. Piersa, J.; Bajek, W.; Pilśniak, A.; Jarosińska, A.; Pietrukaniec, M.; Holecki, M. Nutrition Indicators in Type 2 Diabetes Mellitus—Retrospective Study. Biomedicines 2025, 13, 1137. [Google Scholar] [CrossRef]
  3. Ning, Y.; Pan, D.; Guo, J.; Su, Z.; Wang, J.; Wu, S.; Gu, Y. Association of Prognostic Nutritional Index with the Risk of All-Cause Mortality and Cardiovascular Mortality in Patients with Type 2 Diabetes: NHANES 1999–2018. BMJ Open Diabetes Res. Care 2023, 11, e003564. [Google Scholar] [CrossRef]
  4. Thaenpramun, R.; Komolsuradej, N.; Buathong, N.; Srikrajang, S. Association between Glycaemic Control and Malnutrition in Older Adults with Type 2 Diabetes Mellitus: A Cross-Sectional Study. Br. J. Nutr. 2024, 131, 1497–1505. [Google Scholar] [CrossRef]
  5. Landi, F.; Camprubi-Robles, M.; Bear, D.E.; Cederholm, T.; Malafarina, V.; Welch, A.A.; Cruz-Jentoft, A.J. Muscle Loss: The New Malnutrition Challenge in Clinical Practice. Clin. Nutr. 2019, 38, 2113–2120. [Google Scholar] [CrossRef] [PubMed]
  6. Bao, S.; Jimu, W.; Mu, N.; Yan, F.; Xing, S.; Li, T.; Zhou, Z. Inflammation Mediates the Association between Muscle Mass and Accelerated Phenotypic Aging: Results from the NHANES 2011–2018. Front. Nutr. 2025, 11, 1503702. [Google Scholar] [CrossRef] [PubMed]
  7. Londhe, P.; Guttridge, D.C. Inflammation Induced Loss of Skeletal Muscle. Bone 2015, 80, 131–142. [Google Scholar] [CrossRef]
  8. Pellegrini, V.; La Grotta, R.; Carreras, F.; Giuliani, A.; Sabbatinelli, J.; Olivieri, F.; Berra, C.C.; Ceriello, A.; Prattichizzo, F. Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment. Cells 2024, 13, 1662. [Google Scholar] [CrossRef]
  9. Manilla, V.; Santopaolo, F.; Gasbarrini, A.; Ponziani, F.R. Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer. Nutrients 2023, 15, 2521. [Google Scholar] [CrossRef]
  10. Liu, C.; Feng, X.; Li, Q.; Wang, Y.; Li, Q.; Hua, M. Adiponectin, TNF-α and Inflammatory Cytokines and Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis. Cytokine 2016, 86, 100–109. [Google Scholar] [CrossRef] [PubMed]
  11. Popko, K.; Gorska, E.; Stelmaszczyk-Emmel, A.; Plywaczewski, R.; Stoklosa, A.; Gorecka, D.; Pyrzak, B.; Demkow, U. Proinflammatory Cytokines IL-6 and TNF-α and the Development of Inflammation in Obese Subjects. Eur. J. Med. Res. 2010, 15, 120. [Google Scholar] [CrossRef]
  12. Giovannini, S.; Onder, G.; Liperoti, R.; Russo, A.; Carter, C.; Capoluongo, E.; Pahor, M.; Bernabei, R.; Landi, F. Interleukin-6, C-Reactive Protein, and Tumor Necrosis Factor-Alpha as Predictors of Mortality in Frail, Community-Living Elderly Individuals. J. Am. Geriatr. Soc. 2011, 59, 1679–1685. [Google Scholar] [CrossRef]
  13. Maimunah, U.; Kholili, U.; Putra, R.R.; Brimantyo, D.; Wirantara, H. Increased Levels of TNF-α, IL-6, and IL-10 Are Associated with The Degree of Liver Fibrosis in Chronic Hepatitis B Patients with NUC Therapy. Indones. Biomed. J. 2024, 16, 72–78. [Google Scholar] [CrossRef]
  14. Oladipupo, S.O.; Ezenabor, E.H.; Ojo, A.B.; Ogunlakin, A.D.; Ojo, O.A. Interplay of the Pathophysiological Mechanisms of Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, and Inflammation: A Growing Threat to Public Health. Obes. Med. 2025, 55, 100613. [Google Scholar] [CrossRef]
  15. Ciardullo, S.; Vergani, M.; Perseghin, G. Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment. J. Clin. Med. 2023, 12, 5597. [Google Scholar] [CrossRef] [PubMed]
  16. Lo Buglio, A.; Bellanti, F.; Carapellese, R.M.; Capurso, C.; Serviddio, G.; Vendemiale, G. Adherence to the Mediterranean Diet Mitigates Inflammation and Hospital Stay in Frail Elderly Patients: A Moderation Analysis. Nutrients 2024, 16, 2482. [Google Scholar] [CrossRef] [PubMed]
  17. Bae, M.; Park, Y.-K.; Lee, J.-Y. Food Components with Antifibrotic Activity and Implications in Prevention of Liver Disease. J. Nutr. Biochem. 2018, 55, 1–11. [Google Scholar] [CrossRef] [PubMed]
  18. Bauer, K.C.; Littlejohn, P.T.; Ayala, V.; Creus-Cuadros, A.; Finlay, B.B. Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology 2022, 162, 1858–1875.e2. [Google Scholar] [CrossRef]
  19. Simental-Mendía, L.E.; Rodríguez-Morán, M.; Guerrero-Romero, F. The Product of Fasting Glucose and Triglycerides As Surrogate for Identifying Insulin Resistance in Apparently Healthy Subjects. Metab. Syndr. Relat. Disord. 2008, 6, 299–304. [Google Scholar] [CrossRef]
  20. Tacke, F.; Horn, P.; Wai-Sun Wong, V.; Ratziu, V.; Bugianesi, E.; Francque, S.; Zelber-Sagi, S.; Valenti, L.; Roden, M.; Schick, F.; et al. EASL–EASD–EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). J. Hepatol. 2024, 81, 492–542. [Google Scholar] [CrossRef]
  21. Detsky, A.; McLaughlin; Baker, J.; Johnston, N.; Whittaker, S.; Mendelson, R.; Jeejeebhoy, K. What Is Subjective Global Assessment of Nutritional Status? J. Parenter. Enter. Nutr. 1987, 11, 8–13. [Google Scholar] [CrossRef]
  22. Yuan, Z.; Jiang, C.; Lao, G.; Zhang, Y.; Wang, C.; Zhu, Y.; Chen, C.; Ran, J.; Wang, C.; Zhu, P. Effectiveness of Global Leadership Initiative on Malnutrition and Subjective Global Assessment for Diagnosing Malnutrition and Predicting Wound Healing in Patients with Diabetic Foot Ulcers. Br. J. Nutr. 2024, 132, 21–30. [Google Scholar] [CrossRef]
  23. Karlas, T.; Petroff, D.; Sasso, M.; Fan, J.-G.; Mi, Y.-Q.; de Lédinghen, V.; Kumar, M.; Lupsor-Platon, M.; Han, K.-H.; Cardoso, A.C.; et al. Individual Patient Data Meta-Analysis of Controlled Attenuation Parameter (CAP) Technology for Assessing Steatosis. J. Hepatol. 2017, 66, 1022–1030. [Google Scholar] [CrossRef]
  24. Fritz, M.S.; MacKinnon, D.P. A Graphical Representation of the Mediated Effect. Behav. Res. Methods 2008, 40, 55–60. [Google Scholar] [CrossRef]
  25. Miano, N.; Todaro, G.; Di Marco, M.; Scilletta, S.; Bosco, G.; Di Giacomo Barbagallo, F.; Scicali, R.; Piro, S.; Purrello, F.; Di Pino, A. Malnutrition-Related Liver Steatosis, CONUT Score and Poor Clinical Outcomes in an Internal Medicine Department. Nutrients 2024, 16, 1925. [Google Scholar] [CrossRef]
  26. Haj Ali, S.; Abu Sneineh, A.; Hasweh, R. Nutritional Assessment in Patients with Liver Cirrhosis. World J. Hepatol. 2022, 14, 1694–1703. [Google Scholar] [CrossRef] [PubMed]
  27. Muscaritoli, M.; Imbimbo, G.; Jager-Wittenaar, H.; Cederholm, T.; Rothenberg, E.; di Girolamo, F.G.; Amabile, M.I.; Sealy, M.; Schneider, S.; Barazzoni, R.; et al. Disease-Related Malnutrition with Inflammation and Cachexia. Clin. Nutr. 2023, 42, 1475–1479. [Google Scholar] [CrossRef] [PubMed]
  28. Ghone, R.A. A Study of Oxidative Stress Biomarkers and Effect of Oral Antioxidant Supplementation in Severe Acute Malnutrition. J. Clin. Diagn. Res. 2013, 7, 2146–2148. [Google Scholar] [CrossRef] [PubMed]
  29. Fan, Y.; Yao, Q.; Liu, Y.; Jia, T.; Zhang, J.; Jiang, E. Underlying Causes and Co-Existence of Malnutrition and Infections: An Exceedingly Common Death Risk in Cancer. Front. Nutr. 2022, 9, 814095. [Google Scholar] [CrossRef] [PubMed]
  30. Pérez-Baos, S.; Prieto-Potin, I.; Román-Blas, J.A.; Sánchez-Pernaute, O.; Largo, R.; Herrero-Beaumont, G. Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. Front. Physiol. 2018, 9, 409. [Google Scholar] [CrossRef]
  31. Pourhassan, M.; Cederholm, T.; Trampisch, U.; Volkert, D.; Wirth, R. Inflammation as a Diagnostic Criterion in the GLIM Definition of Malnutrition—What CRP-Threshold Relates to Reduced Food Intake in Older Patients with Acute Disease? Eur. J. Clin. Nutr. 2022, 76, 397–400. [Google Scholar] [CrossRef] [PubMed]
  32. Jee, Y.-M.; Lee, J.-Y.; Ryu, T. Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma. Biomedicines 2025, 13, 1260. [Google Scholar] [CrossRef]
  33. Zhang, Z.; Wang, J.; Li, H.; Niu, Q.; Tao, Y.; Zhao, X.; Zeng, Z.; Dong, H. The Role of the Interleukin Family in Liver Fibrosis. Front. Immunol. 2025, 16, 1497095. [Google Scholar] [CrossRef]
  34. Koyama, Y.; Brenner, D.A. Liver Inflammation and Fibrosis. J. Clin. Investig. 2017, 127, 55–64. [Google Scholar] [CrossRef]
  35. Tauil, R.B.; Golono, P.T.; de Lima, E.P.; de Alvares Goulart, R.; Guiguer, E.L.; Bechara, M.D.; Nicolau, C.C.T.; Yanaguizawa Junior, J.L.; Fiorini, A.M.R.; Méndez-Sánchez, N.; et al. Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols. Pharmaceuticals 2024, 17, 1354. [Google Scholar] [CrossRef]
  36. Suwała, S.; Junik, R. Assessment of the Liver Steatosis and Fibrosis Risk in Metabolic Syndrome and Its Individual Components, Considering the Varying Definitions Used in Clinical Practice throughout Time: A Retrospective Cross-Sectional Study. Biomedicines 2024, 12, 1739. [Google Scholar] [CrossRef]
  37. Riley, D.R.; Hydes, T.; Hernadez, G.; Zhao, S.S.; Alam, U.; Cuthbertson, D.J. The Synergistic Impact of Type 2 Diabetes and MASLD on Cardiovascular, Liver, Diabetes-related and Cancer Outcomes. Liver Int. 2024, 44, 2538–2550. [Google Scholar] [CrossRef]
  38. Rutledge, S.M.; Asgharpour, A. Smoking and Liver Disease. Gastroenterol. Hepatol. 2020, 16, 617–625. [Google Scholar]
  39. Mihara, T.; Hori, M. Nicotine Aggravates Liver Fibrosis via A7 Nicotinic Acetylcholine Receptor Expressed on Activated Hepatic Stellate Cells in Mice. Hepatol. Commun. 2024, 8, e0457. [Google Scholar] [CrossRef] [PubMed]
  40. Hahad, O.; Arnold, N.; Prochaska, J.H.; Panova-Noeva, M.; Schulz, A.; Lackner, K.J.; Pfeiffer, N.; Schmidtmann, I.; Michal, M.; Beutel, M.; et al. Cigarette Smoking Is Related to Endothelial Dysfunction of Resistance, but Not Conduit Arteries in the General Population—Results From the Gutenberg Health Study. Front. Cardiovasc. Med. 2021, 8, 674622. [Google Scholar] [CrossRef] [PubMed]
  41. Wei, Y.; Hägg, S.; Mak, J.K.L.; Tuomi, T.; Zhan, Y.; Carlsson, S. Metabolic Profiling of Smoking, Associations with Type 2 Diabetes and Interaction with Genetic Susceptibility. Eur. J. Epidemiol. 2024, 39, 667–678. [Google Scholar] [CrossRef]
  42. Dhananjayan, R.; Koundinya, K.S.S.; Malati, T.; Kutala, V.K. Endothelial Dysfunction in Type 2 Diabetes Mellitus. Indian J. Clin. Biochem. 2016, 31, 372–379. [Google Scholar] [CrossRef]
  43. Gao, V.; Long, M.T.; Singh, S.R.; Kim, Y.; Zhang, X.; Rogers, G.; Jacques, P.F.; Levy, D.; Ma, J. A Healthy Diet Is Associated with a Lower Risk of Hepatic Fibrosis. J. Nutr. 2023, 153, 1587–1596. [Google Scholar] [CrossRef] [PubMed]
  44. Perez-Diaz-del-Campo, N.; Castelnuovo, G.; Rosso, C.; Nicolosi, A.; Guariglia, M.; Dileo, E.; Armandi, A.; Caviglia, G.P.; Bugianesi, E. Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD. Nutrients 2023, 15, 3018. [Google Scholar] [CrossRef] [PubMed]
  45. Pickett-Blakely, O.; Young, K.; Carr, R.M. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis. Cell. Mol. Gastroenterol. Hepatol. 2018, 6, 451–462. [Google Scholar] [CrossRef]
  46. Esposito, K.; Maiorino, M.I.; Bellastella, G.; Panagiotakos, D.B.; Giugliano, D. Mediterranean Diet for Type 2 Diabetes: Cardiometabolic Benefits. Endocrine 2017, 56, 27–32. [Google Scholar] [CrossRef] [PubMed]
  47. Oguntibeju, O.O. Type 2 Diabetes Mellitus, Oxidative Stress and Inflammation: Examining the Links. Int. J. Physiol. Pathophysiol. Pharmacol. 2019, 11, 45–63. [Google Scholar]
  48. Chen, T.; Zuo, X.; Wang, S.; Yu, P.; Yuan, J.; Wei, S.; Chen, J.; Sun, Y.; Gao, Y.; Li, X. The Effect of Vitamin D Supplementation on the Progression of Fibrosis in Patients with Chronic Liver Disease. Medicine 2020, 99, e20296. [Google Scholar] [CrossRef]
  49. Ng, C.H.; Lim, W.H.; Hui Lim, G.E.; Hao Tan, D.J.; Syn, N.; Muthiah, M.D.; Huang, D.Q.; Loomba, R. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 2023, 21, 931–939.e5. [Google Scholar] [CrossRef]
  50. Saarinen, K.; Färkkilä, M.; Jula, A.; Erlund, I.; Vihervaara, T.; Lundqvist, A.; Åberg, F. Enhanced Liver Fibrosis® Test Predicts Liver-Related Outcomes in the General Population. JHEP Rep. 2023, 5, 100765. [Google Scholar] [CrossRef]
Biomolecules 15 01735 g001
Figure 1. Conceptual framework for the mediation analysis. Path c (top panel) represents the total effect of malnutrition (X) on liver stiffness (Y). Paths a and b represent the indirect effect of malnutrition on liver stiffness via inflammation (M). Path c′ represents the direct effect of malnutrition on liver stiffness after adjusting for inflammation.
Figure 1. Conceptual framework for the mediation analysis. Path c (top panel) represents the total effect of malnutrition (X) on liver stiffness (Y). Paths a and b represent the indirect effect of malnutrition on liver stiffness via inflammation (M). Path c′ represents the direct effect of malnutrition on liver stiffness after adjusting for inflammation.
Biomolecules 15 01735 g001
Biomolecules 15 01735 g002
Figure 2. Venn diagram illustrates the distribution of malnutrition and MASLD in the study cohort (n = 87). A total of 32 patients (36.8%) presented with both MASLD and malnutrition. Twenty-six patients (29.9%) had MASLD without malnutrition, while 12 patients (13.8%) were malnourished without MASLD.
Figure 2. Venn diagram illustrates the distribution of malnutrition and MASLD in the study cohort (n = 87). A total of 32 patients (36.8%) presented with both MASLD and malnutrition. Twenty-six patients (29.9%) had MASLD without malnutrition, while 12 patients (13.8%) were malnourished without MASLD.
Biomolecules 15 01735 g002
Biomolecules 15 01735 g003
Figure 3. Forest plot showing the estimated coefficients and 95% confidence intervals from the multivariable linear regression model for predictors of liver stiffness in patients with T2DM. Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; TyG index, triglyceride–glucose index; CRP, C-reactive protein.
Figure 3. Forest plot showing the estimated coefficients and 95% confidence intervals from the multivariable linear regression model for predictors of liver stiffness in patients with T2DM. Abbreviations: MASLD, metabolic dysfunction-associated steatotic liver disease; TyG index, triglyceride–glucose index; CRP, C-reactive protein.
Biomolecules 15 01735 g003
Biomolecules 15 01735 g004
Figure 4. Mediation model of the association between malnutrition (X) and liver stiffness (Y) via inflammation (M). Unstandardized regression coefficients (B) and p-values are shown for each path. Solid arrows indicate statistically significant effects. All models adjusted for age and sex.
Figure 4. Mediation model of the association between malnutrition (X) and liver stiffness (Y) via inflammation (M). Unstandardized regression coefficients (B) and p-values are shown for each path. Solid arrows indicate statistically significant effects. All models adjusted for age and sex.
Biomolecules 15 01735 g004
Biomolecules 15 01735 g005
Figure 5. Graphical representation of the mediation mechanism.
Figure 5. Graphical representation of the mediation mechanism.
Biomolecules 15 01735 g005
Table 1. Prevalence of comorbidities in the study population.
Table 1. Prevalence of comorbidities in the study population.
Comorbiditiesn
Hypertension54 (62)
Dyslipidemia70 (80.5)
Chronic Kidney Disease11 (12.6)
Ischemic Heart Disease8 (9.2)
Atrial fibrillation6 (6.9)
Heart failure6 (6.9)
Chronic obstructive pulmonary disease4 (4.6)
Stroke3 (3.4)
Active smokers24 (27.6%)
Data are represented as n (%).
Table 2. Baseline characteristics of the patients according to nutritional status.
Table 2. Baseline characteristics of the patients according to nutritional status.
Well-Fed
(SGA A)
n. 43 (49.4%)		Malnourished
(SGA B + C)
n. 44 (50.6%)		p Value
Age, years66.0 [55.0–71.0]68.0 [62.0–74.0]0.118
Genre F, n (%)15 (34.9)13 (29.5)0.651
BMI, Kg/m227.7 ± 5.629.2 ± 6.10.227
Haemoglobin, g/dL14.4 ± 1.813.6 ± 2.20.066
WBC, n/mm37389 ± 28026148 ± 20530.022
Neutrophils, n/mm34518 ± 19093751 ± 14630.038
Lymphocytes, n/mm32060 [1570–2540]1660 [1100–2275]0.041
Platelet, 103/mcL234 ± 72202 ± 880.072
Glucose, mg/dL126.8 ± 25.4130.1 ± 38.30.065
Albumin, g/dL4.4 ± 0.54.3 ± 0.50.132
Creatinine, mg/dL0.94 ± 0.331.02 ± 0.50.384
HbA1c, %7.1 ± 1.07.8 ± 1.210.010
Total cholesterol, mg/dL174.9 ± 38.0144.9 ± 35.7<0.001
LDL, mg/dL105.3 ± 28.778.1 ± 27.4<0.001
HDL, mg/dL47.3 ± 10.457.4 ± 14.40.977
Triglycerides, mg/dL91 [79–130]92 [65–138]0.975
CRP, ng/mL3.5 [2.1–5.4]4.4 [3.1–6.7]0.018
TyG index8.5 ± 0.58.8 ± 0.70.050
Charlson index5 [3–7]7 [5–9]0.042
Active smokers13 (30.2)11 (25%)0.637
MASLD26 (60.5)32 (72.7)0.261
SGLT2-i/GLP-1 agonist14 (32.6)23 (52.3)0.083
Liver stiffness, kPa5.3 ± 2.28.0 ± 2.1<0.001
CAP, dB/m251.8 ± 61.8271.5 ± 60.60.336
Data are reported as mean (±SD), median [IQR] or n (%) as appropriate. Abbreviations: F, female; WBC, white blood cells; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CAP (Controlled attenuation parameter). p value < 0.05 were considered statistically significant (in bold).
Table 3. Linear regression analyses evaluating the impact of nutritional status, inflammation, and metabolic risk on liver stiffness.
Table 3. Linear regression analyses evaluating the impact of nutritional status, inflammation, and metabolic risk on liver stiffness.
Univariate Linear Regression Multivariate Linear Regression
Coefficient B95% CIp  ValueCoefficient B95% CIp Value
BMI, Kg/m20.07−0.03–0.170.179   
HbA1c, %0.590.120–1.050.0140.01−0.36–0.360.993
CRP, ng/mL0.480.29–0.98<0.0010.320.15–0.48<0.001
TyG index1.650.79–2.50<0.0010.65−0.03–1.340.061
Hypertension0.86−0.28–1.990.138   
CKD−0.75−2.47–0.980.392   
Dyslipidemia0.24−1.17–1.640.737   
Heart failure0.49−1.79–2.780.669   
ICHD−0.96−2.91–0.990.329   
Atrial fibrillation0.44−1.79–2.680.695   
Stroke0.53−2.54–3.600.732   
COPD−1.28−3.96–1.390.343   
MASLD2.301.21–3.39<0.0011.540.70–2.380.001
Malnutrition2.972.04–3.90<0.0012.291.48–3.10<0.001
Charlson index0.07−0.12–0.260.449   
Active smokers1.240.02–2.460.0471.060.22–1.890.014
SGLT2-i/GLP-1 agonist1.1−0.03–2.240.06   
Univariate and multivariate models were performed to explore associations with liver stiffness. Abbreviations: CRP, C-reactive protein; CKD, chronic kidney disease; ICHD, ischemic heart disease; COPD, chronic obstructive pulmonary disease; MASLD, metabolic dysfunction-associated steatotic liver disease; TyG, triglyceride–glucose index; HbA1c, glycated hemoglobin; SGLT2-i, sodium-glucose cotransporter-2 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lo Buglio, A.; Bellanti, F.; Villani, R.; Capurso, C.; Magnati, G.P.; Cioffi, S.; Tedesco, G.; Torsello, C.A.; Vendemiale, G.; Serviddio, G. Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation. Biomolecules 2025, 15, 1735. https://doi.org/10.3390/biom15121735

AMA Style

Lo Buglio A, Bellanti F, Villani R, Capurso C, Magnati GP, Cioffi S, Tedesco G, Torsello CA, Vendemiale G, Serviddio G. Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation. Biomolecules. 2025; 15(12):1735. https://doi.org/10.3390/biom15121735

Chicago/Turabian Style

Lo Buglio, Aurelio, Francesco Bellanti, Rosanna Villani, Cristiano Capurso, Grazia Pia Magnati, Sara Cioffi, Gabriele Tedesco, Carlo Alberto Torsello, Gianluigi Vendemiale, and Gaetano Serviddio. 2025. "Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation" Biomolecules 15, no. 12: 1735. https://doi.org/10.3390/biom15121735

APA Style

Lo Buglio, A., Bellanti, F., Villani, R., Capurso, C., Magnati, G. P., Cioffi, S., Tedesco, G., Torsello, C. A., Vendemiale, G., & Serviddio, G. (2025). Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation. Biomolecules, 15(12), 1735. https://doi.org/10.3390/biom15121735

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop